205 results on '"Fernandez-Barrena, Maite G."'
Search Results
2. Caspases compromise SLU7 and UPF1 stability and NMD activity during hepatocarcinogenesis
3. New insights into the regulation of bile acids synthesis during the early stages of liver regeneration: A human and experimental study
4. Loss of liver function in chronic liver disease: An identity crisis
5. FRI-466-YI Implications and therapeutic potential of neddylation for pediatric liver cancer: hepatoblastoma
6. FRI-464 Caspases compromise SLU7 and UPF1 stability and nonsensemediated RNA decay activity during hepatocarcinogenesis
7. FRI-555 New insights into the regulation of bile acids synthesis during the early stages of liver regeneration: a human and experimental study
8. Metabolic-associated fatty liver disease: From simple steatosis toward liver cirrhosis and potential complications. Proceedings of the Third Translational Hepatology Meeting, organized by the Spanish Association for the Study of the Liver (AEEH)
9. New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming
10. Epigenetic remodelling in human hepatocellular carcinoma
11. Non-mitogenic FGF19 mRNA-based therapy for the treatment of experimental metabolic dysfunction-associated steatotic liver disease (MASLD).
12. Fragile X mental retardation protein in intrahepatic cholangiocarcinoma: regulating the cancer cell behavior plasticity at the leading edge
13. Epigenetics in hepatocellular carcinoma development and therapy: The tip of the iceberg
14. Current and novel therapeutic opportunities for systemic therapy in biliary cancer
15. Impact of G9a and DNMT1 expression in pancreatic cancer survival: new potential epigenetic therapeutic strategy
16. Therapeutic potential of targeting protein hyper-SUMOylation in cholangiocarcinoma
17. Pediatric liver cancer: Hepatoblastoma and Neddylation post-translational modification
18. Biomarkers of endothelial dysfunction in patients with non-alcoholic fatty liver disease (NAFLD)
19. Identification and experimental validation of druggable epigenetic targets in hepatoblastoma
20. Single-cell RNA sequencing in DIAMOND mice reveals differentially regulated pathways specifically associated with the transition from simple steatosis towards NASH
21. KLF5 upregulation is a common event in cholangiocarcinoma, acting as an oncogene and constituting a bad prognostic factor
22. Antitumoral activity of the G9a inhibitor EZM8266 in hepatocellular carcinoma: potential for combination with immune checkpoint inhibitors
23. Correction: Current and novel therapeutic opportunities for systemic therapy in biliary cancer
24. Supplementary Figure Legend from IKBKE Is Required during KRAS-Induced Pancreatic Tumorigenesis
25. Supplementary Figures 1 through 6 from IKBKE Is Required during KRAS-Induced Pancreatic Tumorigenesis
26. Data from IKBKE Is Required during KRAS-Induced Pancreatic Tumorigenesis
27. Data from GLI1 Inhibition Promotes Epithelial-to-Mesenchymal Transition in Pancreatic Cancer Cells
28. Supplementary Methods and Materials, Figures 1-9 from GLI1 Inhibition Promotes Epithelial-to-Mesenchymal Transition in Pancreatic Cancer Cells
29. WED-457 - Biomarkers of endothelial dysfunction in patients with non-alcoholic fatty liver disease (NAFLD)
30. DNA methylation regulates lncRNAs compromising hepatic identity during hepatocarcinogenesis
31. Targeting NAE1-mediated protein hyper-NEDDylation halts cholangiocarcinogenesis and impacts on tumor-stroma crosstalk in experimental models
32. Proteomic analysis of bile in the rat thioacetamide model reveals new mechanisms in human cholangiocarcinogenesis
33. The inhibition of the epigenetic efectors DNMT1 and G9a as a potential therapeutic strategy against the non-alcoholic fatty liver development
34. Plasma cell-free DNA methylation as biomarker for hepatocellular carcinoma
35. FRI-538 Novel regulatory mechanisms of the transforming growth factor β signaling pathway by the histone Methyltransferase G9a
36. Targeting NAE1-mediated protein hyper-NEDDylation halts cholangiocarcinogenesis and impacts on tumor-stroma crosstalk in experimental models
37. Fibroblast growth factor 15/19 (FGF15/19) protects from diet-induced hepatic steatosis: development of an FGF19-based chimeric molecule to promote fatty liver regeneration
38. List of Contributors
39. Additional file 1 of New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming
40. Ileal FGF15 contributes to fibrosis-associated hepatocellular carcinoma development
41. FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted
42. Dual Targeting of G9a and DNA Methyltransferase‐1 for the Treatment of Experimental Cholangiocarcinoma
43. Inhibition of metalloprotease hyperactivity in cystic cholangiocytes halts the development of polycystic liver diseases
44. Identification of novel non-coding RNA-based negative feedback regulating the expression of the oncogenic transcription factor GLI1
45. TOP-090 - Single-cell RNA sequencing in DIAMOND mice reveals differentially regulated pathways specifically associated with the transition from simple steatosis towards NASH
46. SAT-247 - Pediatric liver cancer: Hepatoblastoma and Neddylation post-translational modification
47. SAT-232 - Identification and experimental validation of druggable epigenetic targets in hepatoblastoma
48. SAT-223 - Therapeutic potential of targeting protein hyper-SUMOylation in cholangiocarcinoma
49. SAT-226 - KLF5 upregulation is a common event in cholangiocarcinoma, acting as an oncogene and constituting a bad prognostic factor
50. TOP-072 - Antitumoral activity of the G9a inhibitor EZM8266 in hepatocellular carcinoma: potential for combination with immune checkpoint inhibitors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.